Literature DB >> 31209776

Cerebral Vascular Toxicity of Antiretroviral Therapy.

Luc Bertrand1, Martina Velichkovska1, Michal Toborek2.   

Abstract

HIV infection is associated with comorbidities that are likely to be driven not only by HIV itself, but also by the toxicity of long-term use of antiretroviral therapy (ART). Indeed, increasing evidence demonstrates that the antiretroviral drugs used for HIV treatment have toxic effects resulting in various cellular and tissue pathologies. The blood-brain barrier (BBB) is a modulated anatomophysiological interface which separates and controls substance exchange between the blood and the brain parenchyma; therefore, it is particularly exposed to ART-induced toxicity. Balancing the health risks and gains of ART has to be considered in order to maximize the positive effects of therapy. The current review discusses the cerebrovascular toxicity of ART, with the focus on mitochondrial dysfunction. Graphical Abstract Graphical representation of the interactions between HIV, antiretroviral therapy (ART), and the blood-brain barrier (BBB).

Entities:  

Keywords:  Antiretroviral therapy; Blood-brain barrier; Cerebrovascular toxicity; Mitochondria; Neurotoxicity

Mesh:

Substances:

Year:  2019        PMID: 31209776      PMCID: PMC7952282          DOI: 10.1007/s11481-019-09858-x

Source DB:  PubMed          Journal:  J Neuroimmune Pharmacol        ISSN: 1557-1890            Impact factor:   4.147


  152 in total

1.  Inhibition of N-acetylaspartate production: implications for 1H MRS studies in vivo.

Authors:  T E Bates; M Strangward; J Keelan; G P Davey; P M Munro; J B Clark
Journal:  Neuroreport       Date:  1996-05-31       Impact factor: 1.837

Review 2.  Efavirenz and the CNS: what we already know and questions that need to be answered.

Authors:  Nadezda Apostolova; Haryes A Funes; Ana Blas-Garcia; Maria J Galindo; Angeles Alvarez; Juan V Esplugues
Journal:  J Antimicrob Chemother       Date:  2015-07-22       Impact factor: 5.790

3.  Compromising mitochondrial function with the antiretroviral drug efavirenz induces cell survival-promoting autophagy.

Authors:  Nadezda Apostolova; Leysa J Gomez-Sucerquia; Anna Gortat; Ana Blas-Garcia; Juan V Esplugues
Journal:  Hepatology       Date:  2011-08-02       Impact factor: 17.425

4.  The HIV protease inhibitor indinavir down-regulates the expression of the pro-angiogenic MT1-MMP by human endothelial cells.

Authors:  Giovanni Barillari; André Iovane; Ilaria Bacigalupo; Catherine Labbaye; Chiara Chiozzini; Leonardo Sernicola; Maria Teresa Quaranta; Mario Falchi; Cecilia Sgadari; Barbara Ensoli
Journal:  Angiogenesis       Date:  2014-04-10       Impact factor: 9.596

5.  Involvement of nitric oxide in the mitochondrial action of efavirenz: a differential effect on neurons and glial cells.

Authors:  Nadezda Apostolova; Haryes A Funes; Ana Blas-Garcia; Fernando Alegre; Miriam Polo; Juan V Esplugues
Journal:  J Infect Dis       Date:  2014-12-23       Impact factor: 5.226

Review 6.  Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action.

Authors:  Caroline Bazzoli; Vincent Jullien; Clotilde Le Tiec; Elisabeth Rey; France Mentré; Anne-Marie Taburet
Journal:  Clin Pharmacokinet       Date:  2010       Impact factor: 6.447

7.  Prevalence of cognitive disorders differs as a function of age in HIV virus infection.

Authors:  James T Becker; Oscar L Lopez; Mary Amanda Dew; Howard J Aizenstein
Journal:  AIDS       Date:  2004-01-01       Impact factor: 4.177

8.  Impact of darunavir, atazanavir and lopinavir boosted with ritonavir on cultured human endothelial cells: beneficial effect of pravastatin.

Authors:  Martine Auclair; Pauline Afonso; Emilie Capel; Martine Caron-Debarle; Jacqueline Capeau
Journal:  Antivir Ther       Date:  2014-02-17

9.  Common clinical conditions - age, low BMI, ritonavir use, mild renal impairment - affect tenofovir pharmacokinetics in a large cohort of HIV-infected women.

Authors:  Sanjiv M Baxi; Ruth M Greenblatt; Peter Bacchetti; Rebecca Scherzer; Howard Minkoff; Yong Huang; Kathryn Anastos; Mardge Cohen; Stephen J Gange; Mary Young; Michael G Shlipak; Monica Gandhi
Journal:  AIDS       Date:  2014-01-02       Impact factor: 4.177

10.  Antiretroviral drugs induce oxidative stress and neuronal damage in the central nervous system.

Authors:  Cagla Akay; Michael Cooper; Akinleye Odeleye; Brigid K Jensen; Michael G White; Fair Vassoler; Patrick J Gannon; Joseph Mankowski; Jamie L Dorsey; Alison M Buch; Stephanie A Cross; Denise R Cook; Michelle-Marie Peña; Emily S Andersen; Melpo Christofidou-Solomidou; Kathryn A Lindl; M Christine Zink; Janice Clements; R Christopher Pierce; Dennis L Kolson; Kelly L Jordan-Sciutto
Journal:  J Neurovirol       Date:  2014-01-14       Impact factor: 2.643

View more
  18 in total

Review 1.  HIV-Proteins-Associated CNS Neurotoxicity, Their Mediators, and Alternative Treatments.

Authors:  Adonira Saro; Zhaolin Gao; Piniel Alphayo Kambey; Paul Pielnaa; Dama Faniriantsoa Henrio Marcellin; Aixiang Luo; Ruping Zheng; Zhongjun Huang; Lvshuang Liao; Mingxuan Zhao; Liangpeng Suo; Shuang Lu; Min Li; Deyang Cai; Dan Chen; Haiyang Yu; Jufang Huang
Journal:  Cell Mol Neurobiol       Date:  2021-09-25       Impact factor: 4.231

Review 2.  The Impact of Antiretroviral Therapy on Neurocognitive Outcomes Among People Living with HIV in Low- and Middle-Income Countries (LMICs): A Systematic Review.

Authors:  Henry Ukachukwu Michael; Sasha Naidoo; Kofi Boamah Mensah; Suvira Ramlall; Frasia Oosthuizen
Journal:  AIDS Behav       Date:  2021-02

Review 3.  HIV Associated Risk Factors for Ischemic Stroke and Future Perspectives.

Authors:  Saifudeen Ismael; Mohammad Moshahid Khan; Prashant Kumar; Sunitha Kodidela; Golnoush Mirzahosseini; Santhosh Kumar; Tauheed Ishrat
Journal:  Int J Mol Sci       Date:  2020-07-26       Impact factor: 5.923

4.  Enhanced target cell specificity and uptake of lipid nanoparticles using RNA aptamers and peptides.

Authors:  Roslyn M Ray; Anders Højgaard Hansen; Maria Taskova; Bernhard Jandl; Jonas Hansen; Citra Soemardy; Kevin V Morris; Kira Astakhova
Journal:  Beilstein J Org Chem       Date:  2021-04-26       Impact factor: 2.883

5.  Polypharmacy, Medication-Related Burden and Antiretroviral Therapy Adherence in People Living with HIV Aged 50 and Above: A Cross-Sectional Study in Hunan, China.

Authors:  Chunyuan Zheng; Jingjing Meng; Xueling Xiao; Ying Xie; Di Zhao; Honghong Wang
Journal:  Patient Prefer Adherence       Date:  2022-01-07       Impact factor: 2.711

6.  Higher Comorbidity Burden Predicts Worsening Neurocognitive Trajectories in People with Human Immunodeficiency Virus.

Authors:  Ronald J Ellis; Emily Paolillo; Rowan Saloner; Robert K Heaton
Journal:  Clin Infect Dis       Date:  2022-04-28       Impact factor: 20.999

7.  Spatial Distribution Profiles of Emtricitabine, Tenofovir, Efavirenz, and Rilpivirine in Murine Tissues Following In Vivo Dosing Correlate with Their Safety Profiles in Humans.

Authors:  Herana Kamal Seneviratne; Allyson N Hamlin; Carley J S Heck; Namandjé N Bumpus
Journal:  ACS Pharmacol Transl Sci       Date:  2020-04-23

8.  Neuroinflammatory Profiling in SIV-Infected Chinese-Origin Rhesus Macaques on Antiretroviral Therapy.

Authors:  Antonio Solis-Leal; Summer Siddiqui; Fei Wu; Mahesh Mohan; Wenhui Hu; Lara A Doyle-Meyers; Jason P Dufour; Binhua Ling
Journal:  Viruses       Date:  2022-01-13       Impact factor: 5.818

9.  Systemic steroids may enhance recovery from loss of smell and taste in hospitalized coronavirus disease 2019 (COVID-19) patients: an observational study.

Authors:  Luca Giovanni Locatello; Benedetta Trotta; Chiara Bruno; Michele Trotta; Giandomenico Maggiore; Laura Rasero; Saverio Caini; Oreste Gallo
Journal:  Int Forum Allergy Rhinol       Date:  2021-06-16       Impact factor: 5.426

10.  Associations between plasma nucleoside reverse transcriptase inhibitors concentrations and cognitive function in people with HIV.

Authors:  Davide De Francesco; Xinzhu Wang; Laura Dickinson; Jonathan Underwood; Emmanouil Bagkeris; Daphne S Babalis; Patrick W G Mallon; Frank A Post; Jaime H Vera; Memory Sachikonye; Ian Williams; Saye Khoo; Caroline A Sabin; Alan Winston; Marta Boffito
Journal:  PLoS One       Date:  2021-07-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.